Patents by Inventor Makio Hayakawa

Makio Hayakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100055714
    Abstract: The present invention provides an isolated nucleic acid molecules encoding I?B kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (I?B) that inhibits the activity of the NF-?B transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an I?B protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Application
    Filed: October 31, 2007
    Publication date: March 4, 2010
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Patent number: 7314615
    Abstract: The present invention provides an isolated nucleic acid molecules encoding I?B kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (I?B) that inhibits the activity of the NF-?B transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an I?B protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: January 1, 2008
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Publication number: 20040228849
    Abstract: The present invention provides an isolated nucleic acid molecules encoding IKB kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (I&kgr;B) that inhibits the activity of the NF-&kgr;B transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an I&kgr;B protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Application
    Filed: December 17, 2003
    Publication date: November 18, 2004
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Patent number: 6689575
    Abstract: The present invention provides an isolated nucleic acid molecules encoding I&kgr;B kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (I&kgr;B) that inhibits the activity of the NF-&kgr;B transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an I&kgr;B protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 10, 2004
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Publication number: 20020045235
    Abstract: The present invention provides an isolated nucleic acid molecules encoding I&kgr;B kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (I&kgr;B) that inhibits the activity of the NF-&kgr;B transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an I&kgr;B protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Application
    Filed: February 28, 2001
    Publication date: April 18, 2002
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Patent number: 6268194
    Abstract: The present invention provides a substantially purified nucleic acid molecule encoding a serine protein kinase (I&kgr;B kinase) that phosphorylates a protein (I&kgr;B) that inhibits the activity of the NF-&kgr;B transcription factor, vectors comprising such a nucleic acid molecule and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides a substantially purified I&kgr;B kinase, which is a polypeptide that can phosphorylate an I&kgr;B protein, and peptide portions of the I&kgr;B kinase. In addition, the invention provides anti-I&kgr;B kinase antibodies, which specifically bind to an I&kgr;B kinase, and I&kgr;B kinase-binding fragments of such antibodies.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: July 31, 2001
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi
  • Patent number: 6242253
    Abstract: The present invention provides an isolated nucleic acid molecules encoding IKB kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (IKB) that inhibits the activity of the NF-KB transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an IKB protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies.
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: June 5, 2001
    Assignee: Regents of the University of California
    Inventors: Michael Karin, Joseph A. DiDonato, David M. Rothwarf, Makio Hayakawa, Ebrahim Zandi